Nephros Stock Story

NEPH

- USA Stock

USD 2.27 0.22 10.73%

Macroaxis Story

Nephros Invested Capital is most likely to increase significantly in the upcoming years. The last year's value of Invested Capital was reported at 9.17 Million. The current Invested Capital Average is estimated to increase to about 8.4 M, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are projected to decrease to (4.6 M). If you are looking to grow your portfolio over time, you may want to concentrate on all of the essential basic indicators of your selected equities before buying their shares. In this article, we will concentrate on Nephros. I will address the reasons this entity was abused by stockholders resulted from the current market uncertainty. Will stockholders continue to hold, or should we expect a sell-off?

Published over three months ago

View all stories for Nephros | View All Stories

How Nephros (NASDAQ:NEPH) fragile basic indicators helped with the current drop?

Nephros is UNDERVALUED at 8.76 per share with modest projections ahead.

Nephros has Sharpe Ratio of -0.0757, which conveys that the firm had -0.0757% of return per unit of risk over the last 3 months. Macroaxis standpoint towards estimating the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and technical indicators. Nephros exposes twenty-eight different technical indicators, which can help you to evaluate volatility that cannot be diversified away. Please be advised to verify Nephros mean deviation of 1.94, and Risk Adjusted Performance of (0.06) to check out the risk estimate we provide.

How Nephros (NASDAQ:NEPH) fragile basic indicators helped with the current drop?

Typically, a company's financial statements are the reports that show the financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Nephros income statement, its balance sheet, and the statement of cash flows. Potential Nephros investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Nephros investors may use each financial statement separately, they are all related. The changes in Nephros's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Nephros's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.

The goal of Nephros fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Nephros performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Nephros shares is the value that is considered the true value of the share. If the intrinsic value of Nephros is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Nephros.

Please read more on our fundamental analysis page.

Are Nephros Earnings Expected to grow?

The future earnings power of Nephros involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Nephros factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Nephros stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Nephros expected earnings.

How does Nephros utilize its cash?

To perform a cash flow analysis of Nephros, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Nephros is receiving and how much cash it distributes out in a given period. The Nephros cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Nephros exotic insider transaction detected

Legal trades by Nephros insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

Nephros insider trading alert for general transaction of stock option (right to buy) by Andrew Astor, President CEO & CFO, on 7th of March 2022. This event was filed by Nephros Inc with SEC on 2022-03-07. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Going after Nephros Financials

Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Nephros is not uncomon. There are few distinct groups of Nephros stakehholders that the SEC considers insiders. Investors usually gain information through their work as corporate directors, officers, or employees. If these individuals share the information with a friend, family, or business partner and the person who receives the information exchanges stock in the company, he or shie is also an insider. Let's take a look at how the ownership of Nephros is distributed among investors.

Ownership Allocation

The market capitalization of Nephros is $68.04 Million. Over half of Nephros outstanding shares are owned by institutional investors. These institutional investors are typically referred to corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutions are subject to different rules and regulation than regular investors in Nephros. Please watch out for any change in the institutional holdings of Nephros as this could mean something significant has changed or about to change at the company. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.

Retail Investors

35.48%

Insiders

12.3%

Institutions

52.22%

	Retail Investors	35.48
	Insiders	12.3
	Institutions	52.22

Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Nephros has an asset utilization ratio of 331.23 percent. This implies that the company is making $3.31 for each dollar of assets. An increasing asset utilization means that Nephros is more efficient with each dollar of assets it utilizes for everyday operations.

Current Assets

16.4 M

Current Assets	16.35 Million	77.29
Assets Non Current	2.81 Million	13.27
Goodwill	2 Million	9.43

Our perspective of the current Nephros rise

Current variance is at 7.1. Nephros exhibits very low volatility with skewness of 0.9 and kurtosis of 1.67. However, we advise investors to further study Nephros technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Nephros' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Nephros' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Nephros Implied Volatility

Nephros' implied volatility exposes the market's sentiment of Nephros stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Nephros' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Nephros stock will not fluctuate a lot when Nephros' options are near their expiration.

Our Takeaway on Nephros Investment

While some companies in the medical instruments & supplies industry are either recovering or due for a correction, Nephros may not be performing as strong as the other in terms of long-term growth potentials. While some stockholders may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Nephros.

Editorial Staff

Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management. View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Nephros. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2022 Macroaxis LLC